Rosuvastatin calcium and process for producing intermediate thereof
US-2024360086-A1 · Oct 31, 2024 · US
Bacterial host strain comprising a mutant SPR gene and having reduced TSP activity
US8969039B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8969039-B2 |
| Application number | US-201113522087-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 13, 2011 |
| Priority date | Jan 14, 2010 |
| Publication date | Mar 3, 2015 |
| Grant date | Mar 3, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides a recombinant gram-negative bacterial cell comprising a mutant spr gene encoding a spr protein having a mutation at one or more amino acids selected from D133, H145, H157, N31, R62, I70, Q73, C94, S95, V98, Q99, R100, L108, Y115, V135, L136, G140, R144 and G147 and wherein the cell has reduced Tsp protein activity compared to a wild-type cell.
First claim
Opening claim text (preview).
The invention claimed is: 1. A recombinant gram-negative bacterial cell comprising: a mutant spr gene that encodes a mutant spr protein having a mutation that is an amino acid substitution at one or more amino acids within the spr protein selected from the group consisting of D133, H145, H157, N31, R62, I70, Q73, C94, S95, V98, Q99, R100, L108, Y115, V135, L136, G140, R144, and G147, wherein the wild type spr protein has the sequence of SEQ ID NO: 21, and a mutation in the Tsp g…
Assignees
Inventors
Classifications
Chemistry & Metallurgy · mapped topic
- C12N9/0006Primary
Chemistry & Metallurgy · mapped topic
- C12N9/52Primary
Chemistry & Metallurgy · mapped topic
- C12N15/70Primary
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US8969039B2 cover?
- The present invention provides a recombinant gram-negative bacterial cell comprising a mutant spr gene encoding a spr protein having a mutation at one or more amino acids selected from D133, H145, H157, N31, R62, I70, Q73, C94, S95, V98, Q99, R100, L108, Y115, V135, L136, G140, R144 and G147 and wherein the cell has reduced Tsp protein activity compared to a wild-type cell.
- Who is the assignee on this patent?
- Ellis Mark, Humphreys David Paul, Ucb Pharma Sa
- What technology area does this patent fall under?
- Primary CPC classification C12N9/0006. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Mar 03 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).